Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies

Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2018 | 07:42pm CET
FILE PHOTO: The logo of Stada Arzneimittel AG is pictured at their headquarters in Bad Vilbel near Frankfurt

FRANKFURT/LONDON (Reuters) - German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.

The sale, which is handled by Jefferies and Deutsche Bank, is worth about 1 billion euros (839.95 million pounds).

Bristol-Myers Squibb (BMS), Stada, CVC and PAI declined to comment while Angelini was not immediately available for comment.

BMS has given bidders a deadline of late November to submit final proposals, the sources said.

The U.S. firm took full control of the unit, which also produces effervescent aspirin and vitamin C, 24 years ago.

It is now looking to concentrate on high-margin prescription drugs, particularly for cancer, and hopes to sell UPSA for a multiple of 7.5 to 8 times its core earnings of 120 million-130 million euros, the sources said.

Germany's Stada, which is backed by private equity firms Bain Capital and Cinven, is widely seen as the frontrunner for the deal as it seeks to build scale through major acquisitions, the sources said.

Italy's Angelini, which is advised by BNP Paribas, is also willing to embark on a big deal, two of the sources said.

The sale initially drew interest from other big industry players including U.S.-run drugmaker Mylan NV and Japanese healthcare firm Taisho Pharmaceutical which subsequently walked away from the process, the sources said.

UPSA generated revenue of 425 million euros in 2017 and employs about 1,500 people in France.

The sale comes amid a series of high-profile deals in the consumer health industry including Procter & Gamble's acquisition of Merck KGaA's vitamin brands in April and GlaxoSmithKline deal to buy Novartis out of their consumer healthcare joint venture for $13 billion.

(Reporting by Arno Schuetze in Frankfurt and Pamela Barbaglia in London; Additional reporting by Stephen Jewkes in Milan and Matthias Blamont in Paris; Editing by Edmund Blair)

By Arno Schuetze and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 1.50% 54.07 Delayed Quote.-11.77%
GLAXOSMITHKLINE 0.64% 1572.4 Delayed Quote.18.11%
MYLAN NV -0.63% 34.92 Delayed Quote.-17.47%
NOVARTIS 0.48% 88.08 Delayed Quote.6.38%
PROCTER & GAMBLE COMPANY -0.01% 93.82 Delayed Quote.2.11%
STADA ARZNEIMITTEL -0.49% 81.38 Delayed Quote.-7.31%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
10:55aImfinzi fails again in MYSTIC trial for first-line NSCLC
AQ
08:48aInvestors Look Past Rout in Tech Stocks -- WSJ
DJ
11/18Why the Corporate Earnings Boom Has Failed to Lift Investors' Spirits
DJ
11/17PFIZER : to Raise Prices On 41 Drugs In January
DJ
11/17PFIZER : to Raise Prices on 41 Drugs -- Update
DJ
11/15BRISTOL-MYERS SQUIBB : Receives Positive CHMP Opinion Recommending Approval of O..
BU
11/14BRISTOL MYERS SQUIBB : FDA Approves Empliciti Combination for Relapsed or Refrac..
AQ
11/13Nektar makes case for NKTR-214 optimism
AQ
11/11BRISTOL MYERS SQUIBB : Real-World Evidence on Patients Aged 80 and Older Present..
PU
11/08Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit -..
RE
More news
News from SeekingAlpha
11/18CANCER RESEARCH HIGHLIGHT : AstraZeneca Finally Fulfills The Premonitions Of Ill.. 
11/15European advisory group backs Bristol-Myers Squibb's Opdivo + Yervoy in first.. 
11/15CytomX' Translational Data On CX-072 Point Towards A Positive Readout From CX.. 
11/14Bristol-Myers Squibb (BMY) Presents at Credit Suisse Healthcare Conference (T.. 
11/14ZIOPHARM : Elucidating The Regeneron Partnership For Glioblastoma 
Financials ($)
Sales 2018 22 571 M
EBIT 2018 6 170 M
Net income 2018 4 998 M
Finance 2018 991 M
Yield 2018 3,02%
P/E ratio 2018 17,34
P/E ratio 2019 15,40
EV / Sales 2018 3,87x
EV / Sales 2019 3,56x
Capitalization 88 253 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 60,1 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-11.77%88 253
JOHNSON & JOHNSON4.49%391 542
PFIZER20.13%252 358
NOVARTIS6.38%222 056
ROCHE HOLDING LTD.1.54%214 508
MERCK AND COMPANY35.17%197 785